Research

Research

The Sinnett Lab develops and assesses gene therapies for rare neurodevelopmental disorders. Our lab's cornerstone project focuses on treating Rett syndrome (RTT). Our 2021 publication in Brain is the springboard for our lab's ongoing and future endeavors. This publication describes a creative strategy intended to improve the safety of a myc-tagged gene therapy while retaining a survival benefit for mice modeling RTT. This strategy was tailored for RTT and may also be useful or adaptable for other challenging disorders. Ultimately, we want to make impossible gene therapies possible while improving the speed of gene therapy R&D.

In 2022, Health Canada approved a clinical trial application for our RTT gene therapy.